VC Views - Category - VC Views - BioVox - Life sciences Breakthroughs

Join our 20.000 subscribers and receive the monthly newsletter for free!

Why start-ups can become mega companies in the pharma sector

Written by ALB on Tuesday 20 November 2018 in the category VC Views with the tags finance, startup, vc views.

In a previous BioVox article, we analyzed the steps needed for a life sciences start-up to turn into a fully integrated, commercial stage biotech company. For this to happen, the hurdles that need…

Are tech investments under threat by anti-science sentiments?

Written by ALB on Tuesday 30 October 2018 in the category VC Views with the tags vision / opinion / people, regulatory, vc views.

In biotech, company creation is usually preceded by scientific discoveries presenting solutions to existing problems. Because of this, early stage VC investment is, at its core, a science-driven a…

Bringing clinical trials into the home

Written by ALB on Tuesday 2 October 2018 in the category VC Views with the tags drug discovery, clinical trials, vc views.

Lowering the costs of drug development is more important than ever; with the increasing pressure on drug pricing and billions in funding poured into small biotechs, competition is fierce. While th…

Forever young: the science of aging well

Written by ALB on Tuesday 28 August 2018 in the category VC Views with the tags vision / opinion / people, vc views.

“Is aging a disease?” For a long time, the answer to this question seemed obvious: aging is a natural thing that happens to all of us. It is an inevitable side-effect of growing older. However…

Biotechs and subsidies - a fraught relationship

Written by ALB on Monday 23 July 2018 in the category VC Views with the tags finance, vision / opinion / people, vc views.

The ambition of any CEO heading a biotech start-up is to develop a new product and to reach patients quickly. However, drug development comes with long development timelines, making Biotech a capi…

Acquisitions of Biotech companies: a good or a bad thing?

Written by DS on Monday 14 May 2018 in the category VC Views with the tags finance, vision / opinion / people, vc views.

When on the 8th January 2018 the news travelled that Novo Nordisk made a €2.6bn bid for Belgium’s Ablynx, only to be leapfrogged a few weeks later by the € 3.9bn Sanofi bid, we immediately picture…

How to build a “European Amgen”

Written by DS on Thursday 19 April 2018 in the category VC Views with the tags finance, startup, vc views.

There are still very few large European biotech companies to compete with the Amgens and Gileads of the world. Only a handful of European biotech companies have managed to stay independent, grow,…

Is innovation killing the pharmaceutical industry?

Written by DS on Sunday 18 March 2018 in the category VC Views with the tags finance, vision / opinion / people.

In the past few years, the speed at which new drugs have been coming to the market has accelerated significantly [1]. This means there is a lot more competition than before, greatly affecting the …

Artificial intelligence beyond the hype: achievements and expectations in the biotech space

Written by DS on Thursday 18 January 2018 in the category VC Views with the tags bioinformatics, technical innovation, biotech.

Artificial intelligence (AI) is a term that pops up everywhere lately. In this article, we provide some examples of how it opens a plethora of possibilities when it comes to improving healthcare. …

New cures for hereditary diseases around the corner?

Written by JVdB on Monday 18 December 2017 in the category VC Views.

Hereditary diseases are caused by mutations or deletions in (single) genes that lead to either dysfunctional or inadequate levels of proteins. RNA- or DNA-mediated gene supplementation and gene ed…

XpandInnovation UGent V-Bio Ventures GSK Turnstone KU Leuven Flanders.bio Itera Life Science Janssen Biowin

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights.

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.

QUICK LINKS

INSIGHTS ARCHIVE

Read more…

BioVox - Life sciences Breakthroughs

Search

Why start-ups can become mega companies in the pharma sector

Are tech investments under threat by anti-science sentiments?

Bringing clinical trials into the home

Forever young: the science of aging well

Biotechs and subsidies - a fraught relationship

Acquisitions of Biotech companies: a good or a bad thing?

How to build a “European Amgen”

Is innovation killing the pharmaceutical industry?

Artificial intelligence beyond the hype: achievements and expectations in the biotech space

New cures for hereditary diseases around the corner?

ABOUT BIOVOX - Sharing Life Sciences Innovations

QUICK LINKS

INSIGHTS ARCHIVE

PARTNERS

Sign up to our Mailing List to receive updates of our latest News, Events & Magazines

ABOUT BIOVOX - Sharing Life Sciences Innovations

QUICK LINKS

INSIGHTS ARCHIVE

PARTNERS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines